2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.29 Alder

PP01.29 Alder - Abstract

Pdf Summary

The study by Alder et al. examines the impact of STK11 and CDKN2A alterations in non-small cell lung cancer (NSCLC) patients with brain metastases (BrMs). The research analyzed 191 patients with NSCLC and BrMs, focusing on their clinical outcomes based on STK11 or CDKN2A alterations. Results showed that patients with these alterations had a shorter overall survival (OS) and progression-free survival (PFS) compared to those with wild-type genes. Specifically, patients with STK11 alterations had a median OS of 11.8 months from initial metastatic diagnosis and a PFS of 3.8 months from the date of first treatment. Similarly, patients with CDKN2A alterations had a median OS of 14.2 months and a PFS of 3.0 months. The majority of patients in all groups received central nervous system radiation therapy, with a large portion undergoing stereotactic radiosurgery. The study highlights the significant impact of STK11 and CDKN2A alterations on NSCLC patients with BrMs and emphasizes the need for further research to explore their potential as predictive biomarkers and to guide optimal treatment strategies in this population. The research provides unique insights into the clinical outcomes of NSCLC patients with active BrMs carrying these genetic alterations.

Keywords

STK11 alterations

CDKN2A alterations

non-small cell lung cancer

brain metastases

clinical outcomes

overall survival

progression-free survival

central nervous system radiation therapy

stereotactic radiosurgery

predictive biomarkers